Results 141 to 150 of about 100,926 (300)

Incidental Resolution of Dopamine Agonist Induced Impulse Control Disorder with GLP‐1 Receptor Agonist

Movement Disorders Clinical Practice, EarlyView.
Hannah Kelly, Thomas Davis
wiley   +1 more source

Ursodeoxycholic Acid and Parkinson's Disease Risk: An Emulated Target Trial in UK Electronic Health Records

Movement Disorders, EarlyView.
Abstract Background Ursodeoxycholic acid (UDCA) has shown mitochondrial and neuroprotective effects and has been proposed as a treatment for Parkinson's disease (PD). However, population‐level evidence on its effect on PD risk is lacking. Objectives To compare the risk of incident PD among UDCA initiators versus matched non‐initiators within a ...
Chengsheng Ju, Anette Schrag, Camille Carroll, Xi Xiong, James Carpenter, Oliver Bandmann, Thomas Foltynie, Li Wei   +7 more
wiley   +1 more source

Neuropsychiatric and Cognitive Symptom Evolution over the First Decade of Biomarker‐Positive, Sporadic Parkinson's Disease

Movement Disorders, EarlyView.
Abstract Background Parkinson's disease (PD) is frequently accompanied by neuropsychiatric symptoms (NPS), including cognitive impairment, which often emerge early and co‐occur. Their long‐term evolution remains incompletely characterized, particularly in biomarker‐positive cohorts.
Izabelle Schoen, Jing Wang, Sharon X. Xie, Chelsea Caspell‐Garcia, Eugenia Mamikonyan, Melanie Stark, Nabila Dahodwala, Andrew D. Siderowf, Roseanne Dobkin, Michele K. York, Daniel Weintraub   +10 more
wiley   +1 more source

Developing the Dopamine D3 Receptor (D3R) Antagonist, (R)‐VK4‐116, as a Non‐Opioid Medication for the Treatment of Opioid Use Disorder

Medicinal Research Reviews, EarlyView.
ABSTRACT Opioid use disorder (OUD) remains a major global health challenge, and currently approved treatments (methadone, buprenorphine, and naltrexone) are all opioid receptor‐targeting drugs with limitations in access, adherence, stigma, and use in polysubstance use disorders. Because the dopamine D3 receptor (D3R) is enriched in limbic brain regions
Chia‐Kuei Wu, Yu‐Chih Lin, Junfeng Huang, Bangwei Ding, Pramod Terse, Rahul Nandre, Haksong Jin, Molly Congdon, Kun Shen, Philip Sanderson, Gregory Tawa, Stephanie Mounaud, Marta De Santis, Donald Lo, Elizabeth A. Ottinger, Amy Hauck Newman   +15 more
wiley   +1 more source

High Risk of Metabolic Side Effects Among New Paediatric Antipsychotic Users in Sweden-A Register-Based Study. [PDF]

Pharmacoepidemiol Drug Saf
Kimland EE, Sundström A, Wikström S, Jarbin H, Dahlén E.   +4 more
europepmc   +1 more source

Early‐Onset Parkinson's Disease with 22q11.2 Microdeletion and Pathogenic GBA1 Variant

Movement Disorders Clinical Practice, EarlyView.
Nikolai Gil D. Reyes, Daniel G. Di Luca, Ivan Martinez‐Valbuena, Erik Boot, Maria Corral, Ryan K.C. Yuen, Connie Marras, Anthony E. Lang, Anne S. Bassett   +8 more
wiley   +1 more source

Artemia salina Toxicity Assay: Standardization in a 24‐Well Microplate

Environmental Toxicology, EarlyView.
ABSTRACT Bioassays with Artemia sp. are widely used in aquatic, environmental, and human toxicology as an initial tool to investigate the toxicity of plant extracts, isolated compounds, drugs, and products of natural or synthetic origin. These assays allow for the estimation of the median lethal concentration (LC50) and guide subsequent studies in ...
Matheus Pires Miranda, Natalie Petrovna Semanovschi, Roseane Santos de Souza, Angélica Maria Lucchese, Luzimar Gonzaga Fernandez   +4 more
wiley   +1 more source

Repurposing Antipsychotic Agents in Oncology: Mechanistic Rationale, Emerging Evidence, and Therapeutic Potential. [PDF]

Cancers (Basel)
Qu A, Gray K, Fattani S, Ansari S, Hamed H, El-Halawany MS, Mondal D, Makhlouf MM, Abd Elmageed ZY.   +8 more
europepmc   +1 more source

Acute Post‐Partum Psychosis and Dystonia Reveals Late‐Onset MPAN

Movement Disorders Clinical Practice, EarlyView.
Mathilde Lachaume, Audrey Schalk, Nadège Calmels, Christine Tranchant, Ozanne de Andrade, Fabrice Berna, Mathieu Anheim, Thomas Wirth   +7 more
wiley   +1 more source

Opening the Door Wider to Community Support of People With Serious Mental Illnesses: What States Can Learn From the IDD Experience

The Milbank Quarterly, EarlyView.
Policy Points The federal government should provide states with authorities under Medicaid that allow greater use of home and community‐based services for people with serious and persistent mental illness. This requires deemphasizing authorities that require budget neutrality in a post‐institutionalization world (Section 1115 waivers) and relying on ...
HAROLD POLLACK, RICHARD FRANK, SHERRY GLIED   +2 more
wiley   +1 more source